Artelo BiosciencesARTL
About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Employees: 6
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
107% more capital invested
Capital invested by funds: $36.6K [Q4 2024] → $75.8K (+$39.2K) [Q1 2025]
33% more funds holding
Funds holding: 6 [Q4 2024] → 8 (+2) [Q1 2025]
1.57% more ownership
Funds ownership: 1.07% [Q4 2024] → 2.64% (+1.57%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ARTL.
Financial journalist opinion
Based on 3 articles about ARTL published over the past 30 days
